Daoqi You
Overview
Explore the profile of Daoqi You including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1547
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gutierrez-Abril J, Gundem G, Fiala E, Liosis K, Farnoud N, Leongamornlert D, et al.
Blood Adv
. 2025 Feb;
PMID: 39908462
No abstract available.
2.
Paras K, Brunner J, Boyer J, Montero A, Jackson B, Chakraborty S, et al.
bioRxiv
. 2025 Jan;
PMID: 39868247
PAX3-FOXO1, an oncogenic transcription factor, drives a particularly aggressive subtype of rhabdomyosarcoma (RMS) by enforcing gene expression programs that support malignant cell states. Here we show that PAX3-FOXO1 RMS cells...
3.
Worley J, Noh H, You D, Turunen M, Ding H, Paull E, et al.
bioRxiv
. 2024 May;
PMID: 38798673
Statement Of Significance: Network-based approaches, as shown in a study on metastatic breast cancer, can develop effective combinatorial therapies targeting complementary subpopulations. By analyzing scRNA-seq data and using clinically relevant...
4.
Kinnaman M, Zaccaria S, Makohon-Moore A, Arnold B, Levine M, Gundem G, et al.
Cancer Res
. 2023 Oct;
83(22):3796-3812.
PMID: 37812025
Significance: The chemoresistant population in recurrent osteosarcoma is subclonal at diagnosis, emerges at the time of primary resection due to selective pressure from neoadjuvant chemotherapy, and is characterized by unique...
5.
Gundem G, Levine M, Roberts S, Cheung I, Medina-Martinez J, Feng Y, et al.
Nat Genet
. 2023 May;
55(6):1022-1033.
PMID: 37169874
Patients with high-risk neuroblastoma generally present with widely metastatic disease and often relapse despite intensive therapy. As most studies to date focused on diagnosis-relapse pairs, our understanding of the genetic...
6.
Mundi P, Dela Cruz F, Grunn A, Diolaiti D, Mauguen A, Rainey A, et al.
Cancer Discov
. 2023 Apr;
13(6):1386-1407.
PMID: 37061969
Significance: Complementary precision cancer medicine paradigms are needed to broaden the clinical benefit realized through genetic profiling and immunotherapy. In this first-in-class application, we introduce two transcriptome-based tumor-agnostic systems biology...
7.
Kinnaman M, Zaccaria S, Makohon-Moore A, Arnold B, Levine M, Gundem G, et al.
bioRxiv
. 2023 Jan;
PMID: 36711976
Multiple large-scale tumor genomic profiling efforts have been undertaken in osteosarcoma, however, little is known about the spatial and temporal intratumor heterogeneity and how it may drive treatment resistance. We...
8.
Coutinho D, Mundi P, Marks L, Burke C, Ortiz M, Diolaiti D, et al.
Med
. 2022 Oct;
3(11):774-791.e7.
PMID: 36195086
Background: Malignant rhabdoid tumors (MRTs) and Wilms' tumors (WTs) are rare and aggressive renal tumors of infants and young children comprising ∼5% of all pediatric cancers. MRTs are among the...
9.
Dorado Garcia H, Pusch F, Bei Y, von Stebut J, Ibanez G, Guillan K, et al.
Nat Commun
. 2022 Jul;
13(1):4297.
PMID: 35879366
Despite advances in multi-modal treatment approaches, clinical outcomes of patients suffering from PAX3-FOXO1 fusion oncogene-expressing alveolar rhabdomyosarcoma (ARMS) remain dismal. Here we show that PAX3-FOXO1-expressing ARMS cells are sensitive to...
10.
Nunes C, Depestel L, Mus L, Keller K, Delhaye L, Louwagie A, et al.
Sci Adv
. 2022 Jul;
8(28):eabn1382.
PMID: 35857500
High-risk neuroblastoma, a pediatric tumor originating from the sympathetic nervous system, has a low mutation load but highly recurrent somatic DNA copy number variants. Previously, segmental gains and/or amplifications allowed...